(European Society of Cardiology) Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line - LBCT Session at ESC Congress1 and published in the NEJM.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2vCCpZX
No comments:
Post a Comment